BioCryst to Present at Upcoming Investor Conferences
25 Mars 2024 - 9:01PM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the company will present at the H.C. Wainwright 2nd Annual
Autoimmune & Inflammatory Disease Virtual Conference on
Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual
Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at
10:15 a.m. ET.
Links to the live audio webcasts and replays of
the presentations may be accessed in the Investors & Media
section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a
deep commitment to improving the lives of people living with
complement-mediated and other rare diseases. BioCryst leverages its
expertise in structure-guided drug design to develop first-in-class
or best-in-class oral small-molecule and protein therapeutics to
target difficult-to-treat diseases. BioCryst has commercialized
ORLADEYO® (berotralstat), the first oral, once-daily plasma
kallikrein inhibitor, and is advancing a pipeline of small-molecule
and protein therapies. For more information, please visit
www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:John
Bluth+1 919 859 7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024